Research Article
Prognostic Utility of Vitamin D in Acute Coronary Syndrome Patients in Coastal Norway
Table 2
Baseline characteristics of the TnT positive patient population arranged according to the quartiles of 25(OH)D.
| | Characteristics (%) | Quartiles of 25(OH)D | value | | Q1 | Q2 | Q3 | Q4 |
| | 25(OH)D (nmol/L) | 30.2 ± 6.2 | 44.9 ± 3.5 | 56.6 ± 3.6 | 78.1 ± 13.2 | <0.001 | | 25(OH)D (ng/mL) | 12.1 ± 2.5 | 18.0 ± 1.4 | 22.6 ± 1.4 | 31.2 ± 5.3 | <0.001 | | Omega-3 Index | 6.1 ± 1.6 | 6.4 ± 1.6 | 6.9 ± 1.9 | 7.5 ± 2.2 | <0.001 | | Age, years | 72.5 ± 14.8 | 72.6 ± 13.5 | 71.5 ± 13.8 | 71.2 ± 11.0 | 0.809 | | Male, (%) | 64 (55.2) | 81 (69.2) | 73 (62.4) | 86 (74.1) | 0.015 | | Smoking status, (%) | | | | | 0.047 | | Current smoker, (%) | 36 (31.0) | 37 (31.6) | 35 (29.9) | 30 (25.9) | | | Past smoker, (%) | 30 (25.9) | 42 (35.9) | 35 (29.9) | 53 (45.7) | | | Never smoked, (%) | 50 (43.1) | 38 (32.5) | 47 (40.2) | 33 (28.4) | | | Angina pectoris, (%) | 49 (42.2) | 48 (41.0) | 52 (44.4) | 51 (44.0) | 0.949 | | CHF, (%) | | | | | | | Killip Class 2–4 | 56 (48.3) | 27 (23.1) | 30 (25.6) | 32 (27.6) | <0.001 | | History of previous MI, (%) | 46 (39.7) | 37 (31.6) | 35 (29.9) | 38 (32.8) | 0.413 | | CABG, (%) | 11 (9.5) | 7 (6.0) | 12 (10.3) | 12 (10.3) | 0.612 | | PCI, (%) | 9 (7.8) | 9 (7.7) | 7 (6.0) | 10 (8.6) | 0.893 | | Hypertension, (%) | 48 (41.4) | 47 (40.2) | 52 (44.4) | 49 (42.2) | 0.926 | | History of DM 1, (%) | 0 (0.0) | 2 (1.7) | 0 (0.0) | 4 (3.4) | 0.058 | | History of DM 2, (%) | 26 (22.4) | 19 (16.2) | 19 (16.2) | 9 (7.8) | 0.023 | | STEMI, (%) | 29 (25.0) | 35 (29.9) | 30 (25.6) | 33 (28.4) | 0.813 | | eGFR (μmol L−1) | 59.7 ± 23.2 | 59.8 ± 22.3 | 62.5 ± 23.3 | 63.9 ± 23.5 | 0.418 | | Cholesterol/statin, (%) | 53 (45.7) | 54 (46.2) | 52 (44.4) | 50 (43.1) | 0.967 | | Beta-blocker, (%) | 40 (34.5) | 39 (33.3) | 35 (29.9) | 34 (29.3) | 0.793 | | Known CHD, (%) | 80 (69.0) | 71 (60.7) | 76 (65.0) | 72 (62.1) | 0.566 | | BMI (kg/m2) | 25.7 ± 4.5 | 25.9 ± 4.6 | 25.6 ± 4.3 | 25.3 ± 3.9 | 0.714 | | BNP quartiles | | | | | 0.778 | | Q1 | 15 (13.8) | 17 (15.0) | 22 (19.5) | 23 (21.3) | | | Q2 | 24 (22.0) | 23 (20.4) | 25 (22.1) | 24 (22.2) | | | Q3 | 26 (23.9) | 34 (30.1) | 32 (28.3) | 26 (24.1) | | | Q4 | 44 (40.4) | 39 (34.5) | 34 (30.1) | 35 (32.4) | | | hsCRP quartiles | | | | | 0.698 | | Q1 | 18 (15.5) | 22 (18.8) | 19 (16.2) | 27 (23.3) | | | Q2 | 24 (20.7) | 27 (23.1) | 31 (26.5) | 27 (23.3) | | | Q3 | 32 (27.6) | 36 (30.8) | 36 (30.8) | 32 (27.6) | | | Q4 | 42 (36.2) | 32 (27.4) | 31 (26.5) | 30 (25.9) | |
|
|
Mean ± SD.
SD, standard deviation; 25(OH)D, 25-hydroxyvitamin D; CHF, congestive heart failure; MI, myocardial infarction; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention; DM, diabetes mellitus; STEMI, ST-elevation myocardial infarction; TnT, troponin T; eGFR, estimated glomerular filtration rate; CHD, coronary heart disease; BMI, body mass index; BNP, B-type natriuretic peptide; hsCRP, high sensitivity C-reactive protein.
|
